Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Phase 2

Active, not recruiting

Conditions: Autoimmune Hepatitis

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2017-07-14

Last Posted Date: 2025-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03217422

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States

and more 2 locations

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QAW039
Drug: Placebo

First Posted Date: 2017-07-12

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 675

Registration Number: NCT03215758

Locations: 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: NSCLC, Non Small Cell Lung Cancer
RCC, Renal Cell Cancer
Head and Neck Cancer
Pancreatic Cancer
TNBC, Triple Negative Breast Cancer
Melanoma
mCRPC, Metastatic Castration Resistant Prostate Cancer
Urothelial Cancer
DLBCL, Diffused Large B Cell Lymphoma
MSS, Microsatellite Stable Colon Cancer

Interventions: Drug: NIR178
Drug: PDR001

First Posted Date: 2017-07-05

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 315

Registration Number: NCT03207867

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute ., Tampa, Florida, United States
🇺🇸
University of California, Los Angeles, Santa Monica, California, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

and more 3 locations

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

Phase 2

Completed

Conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-07-02

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT03205150

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Phase 2

Terminated

Conditions: Hereditary Hemochromatosis

Interventions: Drug: Deferasirox FCT
Procedure: Phlebotomy

First Posted Date: 2017-06-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03203850

Locations: 🇨🇭
Novartis Investigative Site, Lugano, Switzerland

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2017-06-27

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT03200717

Locations: 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: LIK066
Dietary Supplement: Carbohydrate 50%
Dietary Supplement: Carbohydrate 8%
Dietary Supplement: Carbohydrate 25%
Dietary Supplement: Psyllium
Dietary Supplement: Carbohydrate 0%
Dietary Supplement: Calcium carbonate

First Posted Date: 2017-06-26

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03198767

Locations: 🇺🇸
Novartis Investigative Site, Lincoln, Nebraska, United States

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

Phase 2

Completed

Conditions: Peripheral Artery Disease (PAD); Intermittent Claudication

Interventions: Drug: LLG783
Drug: Placebo

First Posted Date: 2017-06-21

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT03194776

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: PDR001
Drug: bevacizumab
Drug: mFOLFOX6

First Posted Date: 2017-06-05

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03176264

Locations: 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase 3

Completed

Conditions: Post Menopausal Breast Cancer

Interventions: Drug: everolimus
Drug: exemestane

First Posted Date: 2017-06-05

Last Posted Date: 2020-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 235

Registration Number: NCT03176238

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy